

NETRF 2019 RESEARCH SYMPOSIUM PROGRAM
DRAFT AGENDA

May 2-3, 2019
 Norton's Woods Conference Center
 American Academy of Arts & Sciences
 135 Irving Street, Cambridge, MA

Thursday, May 2, 2019
DAY 1

Registration and Breakfast	8:00 – 8:30 am
Introductions and Welcome	8:30 – 8:40 am

Session I: Laboratory Models of NETS **8:40 – 10:20 am**

Talya Dayton, PhD, Hubrecht Institute, Netherlands
Topic: Modeling neuroendocrine neoplasias using adult stem cell-derived organoids

Raj Srirajaskanthan, PhD, Kings College London, United Kingdom
Topic: Development of ex-vivo models of metastatic neuroendocrine tumors

Charlotte Kuperwasser, PhD, Tufts School of Medicine, Whitehead Institute, Massachusetts Institute of Technology, Cambridge, MA
Topic: Development of 3D models for neuroendocrine tumors

Pawel Mazur, PhD, University of Texas M.D. Anderson Cancer Center
Topic: Next generation animal models to define therapies for neuroendocrine tumors

Jesse Boehm, PhD, Broad Institute, Cambridge, MA
Topic: The NETRF/BROAD Cancer Cell Line Factory initiative

Q and A Discussion

Coffee Break **10:20 – 11:00 am**

Session II: Immuno-oncology and NETS **11:00 – 11:55 am**

Xianxin Hua, MD, PhD, University of Pennsylvania, Philadelphia, PA
Topic: Multipronged approaches to develop immunotherapy targeting NETs

Chrissie Thirlwell, MD, PhD, University College London, United Kingdom

Topic: Systematic evaluation of the immune environment of NETs

Renata Jaskula-Sztul, PhD, The University of Alabama at Birmingham

Topic: Novel antibody-drug conjugate (ADC) for PanNET targeted therapy

Q and A Discussion

Lunch 12:00 – 1:30 pm

Session III: Detecting and Targeting NETs 1:30 – 2:25 pm

Babak Behnam Azad, PhD, Johns Hopkins School of Medicine, Baltimore, MD, ERF 2018

Topic: A modified PET tracer for NET detection

Brian Untch, MD, Memorial Sloan Kettering Cancer Center, NY, NY, NANETS 2018

Topic: Somatostatin receptor ligands can be used to image and treat murine panNETs induced by MEN1-loss

Martin Gotthardt, MD, Radboud University Nijmegen Medical Centre, Netherlands

Topic: NETcure - shine new light on neuroendocrine tumor therapy

Q and A Discussion

Coffee Break 2:30– 3:00 pm

Session IV: Advances in NET Treatment: Nuclear Medicine 3:00 – 4:25 pm

Rodney Hicks, MD, University of Melbourne, Australia

Topic: Developing novel combination therapies for use with ¹⁷⁷Lu-octreotate PRRT in NETs, focusing on DNA-repair mechanisms

Cristina Muller, Paul Scherrer, PhD, Institut, Switzerland

Topic: Simultaneous Auger e- and β -particle therapy of metastasized NET using ¹⁶¹Tb-DOTATOC

Thomas Hope, MD, University of California, San Francisco, CA, ERF 2017

Topic: Yttrium-90 DOTA-TOC intra-arterial PRRT for NET

David Morse, PhD, Moffitt Cancer Center, Tampa, FL

Topic: Evaluation of ²²⁵Ac-DOTATATE for treatment of lung carcinoid tumors

Kuo-Shyan Lin, PhD, BC Cancer, Vancouver, Canada,

Topic: Novel radioligands to improve radiotherapy of NETs

Q and A discussion and wrap-up of day by chairs

Reception

4:30 – 5:30 pm

End of Day 1

5:30 pm

Friday, May 3, 2019 DAY 2

Session I: Pre-clinical advances in NETs

8:30 – 9:50 am

Amanda Wasylishen, PhD, (Gigi Lozano Lab), MD Anderson Cancer Center, Houston, TX

Topic: Loss of DAXX and ATRX in development, tissue homeostasis, and pancreatic neuroendocrine tumorigenesis

Joe Zhou, PhD, Weill Cornell Medicine, NY, NY

Topic: Epigenetic regulators of intestinal neuroendocrine cells and carcinoid tumors

Chester Chamberlain, PhD, (Michael German Lab), University of California, San Francisco, CA

Topic: Pathways to Synthetic Lethal Combinations and New Drug Therapies for PNETs

Q and A discussion

Coffee Break

9:50 – 10:20 am

Session II: Cracking the code

10:20 – 12:10 pm

Keynote: William Sellers, MD, Broad Institute

Matthew Meyerson, MD, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA /

Eric Nakakura, MD, PhD, UCSF / Chrissie Thirlwell, MD, PhD, UCL London

Topic: Transcriptomic, genomic and epigenomic analysis of small intestinal NETs

Laura Banaszynski, PhD, UT Southwestern Medical Center, Dallas, TX

Topic: The role of ATRX/DAXX/H3.3 chromatin regulation in PNETs

Sharon Gorski, PhD, Genome Sciences Centre, Canada

Topic: Molecular characterization of primary and metastatic PanNETs

Sita Kugel, PhD, Fred Hutchinson Cancer Research Center, Seattle, Washington

Topic: Exploring the role of epigenetic dysregulation in PanNET progression

Q and A Discussion

Lunch

12:10 – 1:15 pm

Session III: New Clinical Strategies

1:15 – 3:00 pm

Jennifer Chan, MD, MPH, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Topic: Biomarkers of response to cabozantinib in patients with NETs

Emily Bergsland, MD, University of California San Francisco, CA

Topic: New strategies to improve drug development specific to carcinoid tumors

Renuka Iyer, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Topic: Phase 1 study of SurvaxM™ in surviving-positive NETs

Justin Annes, MD, PhD, Stanford University Medical Center, CA

Topic: NET-Smart chemotherapy: a targeted prodrug strategy

-

Q and A Discussion

NETRF Scientific Advisors and Moderators

Panel Discussion: Key take-away points and priorities for future research

Meeting Adjourned